Corporate Strategy

Deallus supports and helps form life science Corporate Strategy by using in-house experience, as well as objective and rigorous analysis of competitive market trends, to guide organisations along their strategic pathway. Our successful approach is based on innovative research methodologies combined with versatile modelling and analytical tools that in summary translate into unrivalled strategic support.

Short, Medium & Long Term Strategy

Issue:

  • Our client, a top-10 pharma company, requested a healthcare ecosystem trend analysis to redirect the organisation’s corporate goals for the ensuing 10 years. They demanded a highly objective analysis, fully externally sourced, devoid from internal biases and opinions.

Solution:

  • Deallus conducted in-depth analysis of external trends out of which were formed a number of plausible scenarios that formed the basis of a live Strategy Simulation Workshop, enabling the various stakeholders to identify opportunities and make prioritized corporate investments. The analysis and the process facilitated by Deallus helped the client distill three main macro areas of focus. Today these form the basis of the company’s transformational process aimed at aligning the company with the most significant market trends.

Issue:

  • Our client, a top-10 bio-pharma company, needed to ‘pressure test’ their ten year corporate differentiation strategy by analysing relevant peer competitor organisations, in order to understand whether particular clusters of ‘strategic archetypes’ of bio-pharma were emerging. The Senior Management was most interested in assessing whether in the long term those companies would encroach with their own space or would rather diverge.

Solution:

  • Deallus used sophisticated analytics to sift through past and projected sales revenues (of top ten pharma) in differently aggregated disease areas. We then built complex indexes to address the directionality of R&D investment and shifts in therapeutic area concentrations. Based on this work the client consolidated assumptions about two critical pharma competitors and initiated a more granular discussion to invest into emerging markets.

Product Portfolio Strategy

Issue:

  • The client required an understanding of the strategic options available to build a new portfolio in a diverse set of emerging markets, followed by an initial business case for 2 key products.

Solution:

  • Deallus carried out internal interviews to clearly understand the company’s capabilities in the target markets, in order to shortlist the most commercially relevant opportunities. Forecasts were then built for two potential portfolio flagship products through targeted market research using both quantitative and qualitative methodologies.

Organizational Effectiveness

Issue:

  • Our client required support in reviewing the role and responsibilities of their commercial support functions in order that they continued to provide maximal value to the organisation as a whole. Particular focus was paid to the shifting requirements of these services based on meeting the diverse demands of regional and local markets and each of the company’s TA-based business units.

Solution:

  • Through best practice analyses our client’s commercial support functions were compared against those of other leading companies, both within and outside of the pharmaceutical industry. Deallus was able to build hypotheses on recent operational and organisational changes, the rationale behind them and their subsequent performance. Through the analysis, we were able to identify a specific operational strategy which enabled the client’s global commercial support function to collaborate efficiently across business units and regions, whilst maintaining the uniformity required to build and maintain a corporate identity.

Innovation Strategy

Issue:

  • Our client, a top-10 bio-pharma company, wanted to understand how innovative pharma companies source their innovation with the aim of identifying approaches that could be adopted within their own organization.

Solution:

  • Deallus performed a comprehensive secondary data analysis to identify and organise various approaches of innovation sourcing ranging from crowd sourcing to M&A as well as preferred partnerships with academia. Based on this work the client gained an understanding of the many different approaches to innovation within the industry and identified two relevant peer competitor companies for further analysis.

Business Unit & Franchise Strategy

Issue:

  • Our client faced major long-term threats from biosimilar manufacturers aiming to enter in the (developed and developing) markets and needed to build a cost-effective strategy to defend their brands globally.

Solution:

  • Deallus went through a process of de-constructing the entire competitor capabilities and the wealth of global clinical development ongoing (or planned) in each market. Following evaluation of the level of interaction the companies had with private and public entities, we were able to project the long-term global strategy of the biosimilar manufacturers (including M&A and other exit strategies available to smaller players). The client was then able to reverse incorrect internal assumptions about the competition and to take on board recommendations for strategic budgeting to offset competitor entry.